Post-Marketing Surveillance of Long-Term Observation of Gliadel Wafer-Investigation of Vital Prognosis in Patients With High Grade Glioma
Phase of Trial: Phase IV
Latest Information Update: 12 Sep 2017
At a glance
- Drugs Carmustine polifeprosan 20 wafer (Primary)
- Indications Glioma
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd
- 12 Sep 2017 Discrepancy was found in the trial status from NCT and Japic registry. As per NCT this trial was completed and as per Japic it is active no longer recruiting. I have sent mail to the investigator for the confirmation and waiting for the reply (_ML_CLNCL@hhc.eisai.co.jp).
- 11 Sep 2017 Planned End Date changed from 1 Feb 2017 to 31 Mar 2017.
- 18 Apr 2017 Status changed from active, no longer recruiting to completed.